BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32962686)

  • 1. Identification of an alternative splicing signature as an independent factor in colon cancer.
    Chen H; Luo J; Guo J
    BMC Cancer; 2020 Sep; 20(1):904. PubMed ID: 32962686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
    Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
    Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma.
    Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J
    J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
    Lai J; Yang H; Xu T
    BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
    Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
    J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.
    Zhang D; Zou D; Deng Y; Yang L
    J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of alternative splicing events and prognostic signatures in breast cancer.
    Han P; Zhu J; Feng G; Wang Z; Ding Y
    BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of relapse-associated alternative mRNA splicing and construction of a prognostic signature predicting relapse in I-III colon cancer.
    Zhang Z; Feng Q; Jia C; Zheng P; Lv Y; Mao Y; Xu Y; He G; Xu J
    Genomics; 2020 Nov; 112(6):4032-4040. PubMed ID: 32645524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data.
    Xu N; Ke ZB; Lin XD; Lin F; Chen SH; Wu YP; Chen YH; Wei Y; Zheng QS
    Aging (Albany NY); 2020 Mar; 12(6):4996-5009. PubMed ID: 32217810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data.
    Zhang D; Zhang W; Sun R; Huang Z
    Bioengineered; 2021 Dec; 12(1):1091-1110. PubMed ID: 33783315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma.
    Xing L; Zhang X; Tong D
    DNA Cell Biol; 2019 Jul; 38(7):627-638. PubMed ID: 31025877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
    Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of prognostic alternative splicing signature in hepatocellular carcinoma.
    Wu F; Chen Q; Liu C; Duan X; Hu J; Liu J; Cao H; Li W; Li H
    Cancer Med; 2020 Mar; 9(6):2171-2180. PubMed ID: 31975560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas.
    Yang L; He Y; Zhang Z; Wang W
    PeerJ; 2019; 7():e8245. PubMed ID: 31844595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods.
    Cai Q; He B; Zhang P; Zhao Z; Peng X; Zhang Y; Xie H; Wang X
    J Transl Med; 2020 Dec; 18(1):463. PubMed ID: 33287830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of drug targets and prognosis projection for uterine carcinosarcoma based on alternative splicing events.
    Zhang X; Yin X; Zhang L; Ye Z; Liang G
    Comput Biol Med; 2023 Jan; 152():106346. PubMed ID: 36470146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer.
    AZhaTi B; Wu G; Zhan H; Liang W; Song Z; Lu L; Xie Q
    World J Surg Oncol; 2022 Jul; 20(1):231. PubMed ID: 35820925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of alternative splicing signatures in the prognosis of glioblastoma.
    Xie ZC; Wu HY; Dang YW; Chen G
    Cancer Med; 2019 Dec; 8(18):7623-7636. PubMed ID: 31674730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
    Liu Y; Jia W; Li J; Zhu H; Yu J
    Front Oncol; 2020; 10():587343. PubMed ID: 33117720
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.